

CORRECTION

Correction to: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer

Lee MR, Woo SM, Kim MK, Han SS, Park SJ, Lee WJ, Lee DE, Choi SI, Choi W, Yoon KA, Chun JW, Kim YH, Kong SY Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. *Cancer Sci.* 2024;115:1283-1295. doi: [10.1111/cas.16104](https://doi.org/10.1111/cas.16104)

In the initially published version of this article, there was a discrepancy in the representation of the last digit of the grant number. The correction has no impact on the result and conclusion of the manuscript.

Below is the corrected funding information:

This study was supported by grants from the NCC (Grant number: NCC-1910192, NCC-2212470 & NCC-2310632).

We apologize for this error.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. *Cancer Science* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.